期刊文献+

血小板糖蛋白Ⅱb/Ⅲa受体拮抗药替罗非班在急性冠状动脉综合征患者血运重建中的应用 被引量:2

原文传递
导出
摘要 目的:为替罗非班在急性冠状动脉综合征患者血运重建中的应用提供参考。方法:本文重点阐述替罗非班的药理特点及其在急性冠状动脉综合征患者经皮冠状动脉介入治疗中的应用现状。结果与结论:替罗非班通过阻断血小板聚集的最终共同通路(GPⅡb/Ⅲa受体),彻底地抑制血小板聚集。适时应用替罗非班不但可以使经皮冠状动脉介入治疗的急性冠状动脉综合征患者在围术期获益,而且能够改善其远期临床预后。
出处 《中国药房》 CAS CSCD 2013年第42期4003-4006,共4页 China Pharmacy
基金 北京市卫生局首都医学发展科研基金资助项目(No.2009-2074)
  • 相关文献

参考文献32

  • 1Egbertson MS, Chang CT, Duggan ME, et al.Non-pepti- de fibrinogen receptor antagonists. 2. Optimization of a ty- rosine template as a mimic for Arg-Gly-Asp[J]J Med Chem, 1994,37(16) : 2 537.
  • 2Badimon L, Vilahur G. Coronary atherothrombotic disea- se: progress in antiplatelet therapy[J]. Rev Esp Cardiol, 2008,61(5):501.
  • 3Ferguson JJ,Zaqqa M.Platelet glycoprotein 11 b/llla recep- tor antagonists: current concepts and lustre directions[J]. Drugs, 1999,58 (6) : 965.
  • 4吴惠珍,李静,吕迁洲.血小板Ⅱb/Ⅲa受体拮抗药盐酸替罗非班临床研究现状[J].中国药房,2008,19(8):627-630. 被引量:32
  • 5Valgimigli M, Campo G, Percoco G, et al.Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial[J].JAMA, 2008,299 ( 15 ) : 1 788.
  • 6Marmur JD, Poludasu S, Agarwal A, et aLHigh-dose tirofi- ban administered as bolus-only during percutaneous coro- nary intervention[J]. J Invasive Cardiol, 2008,20 (2) : 53.
  • 7Batchelor WB, Tolleson TR, Huang Y, et al.Randomized comparison of platelet inhibition with abciximab, tirofi- ban and eptifibatide during percutaneous coronary inter- vention in acute coronary syndromes: the COMPARE tri- al. Comparison of measurements of platelet aggregation with aggrastat, reopro, and eptifibatide[J]. Circulation, 2002,106(12):1 470.
  • 8Holmes MB, Kabbani SS, Terrien CM, et al.Quantifica- tion by flow cytometry of the efficacy of and interindivid- ual variation of platelet inhibition induced by treatment with tirofiban and abciximab. Coron Artery Dis[J]. Coron Artery Dis, 2001,12 (3) : 245.
  • 9Danzi GB, Capuano C, Sesana M, et al.Variability in ex- tent of platelet function inhibition after administration of optimal dose of glycoprotein I/b/1I a receptor blockers in patients undergoing a high-risk percutaneous coronary in- tervention[J]. Am J Cardiol, 2006,97 (4) : 489.
  • 10陈志刚,黄陆力,岳兵,张永春.替罗非班对急性冠状动脉综合征患者经皮冠状动脉介入术后血浆可溶性OX40L的影响[J].中国药房,2012,23(18):1693-1695. 被引量:2

二级参考文献22

共引文献32

同被引文献25

  • 1高丽华,何洪月,胡亚力.1例静脉泵入替罗非班致肾功能衰竭血小板为0病例报告[J].中国中西医结合急救杂志,2008,15(6). 被引量:4
  • 2The Task Force for the management of acute coronary syndromes(ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC).ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J].Eur Heart J,2011,32(23):2999-3054.
  • 3Wikipedia.Tirofiban[EB/OL].[2014-11-12].https://en.wikipedia.org/wiki/Tirofiban.
  • 4耿海明,谢国范,穆惠芳,等.一种抑制血小板凝聚的注射液及其制备方法:中国,1322863 C[P].2007-06-27.
  • 5黄汉伟,龙远德,杨蕊,等.一种盐酸替罗非班杂质及其制备、检测方法:中国,103232387 A[P].2013-08-07.
  • 6黄毅,黄层霄,彭俊,等.盐酸替罗非班注射液及其制备方法:中国,102600072 B[P].2013-10-23.
  • 7李春文.输液中不溶性微粒的临床危害及控制方法探讨[J].华西药学杂志,1992,7(1):69-70.
  • 8Qureshi A H,Chaoji V,Maiguel D,et al.Proteomic and phospho-proteomic profile of human platelets in basal,resting state:insights into integrin signaling[J].PLoS One,2009,4(10):e7627.
  • 9Panduranga P,Sulaiman K.Severe thrombocytopenia following tirofiban infusion[J].Indian J Pharmacol,2011,43(6):726-728.
  • 10Bougie D W, Wilker P R,Wuitschick E D,et al.Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPⅡb/Ⅲa[J].Blood,2002,100(6):2071-2076.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部